ReviewF1000Research2015
Small molecules with antiviral activity against the Ebola virus.
Review in F1000Research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Development and Structural Analysis of Antibody Therapeutics for Filoviruses.Pathogens (Basel, Switzerland) · 2022Review
- Human Coronaviruses: Counteracting the Damage by Storm.Viruses · 2021Review
- Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Déjà vu: Stimulating open drug discovery for SARS-CoV-2.Drug discovery today · 2020Review
- Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.F1000Research · 2020Review
- Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection.PLoS neglected tropical diseases · 2019Article
- The Natural Product Eugenol Is an Inhibitor of the Ebola Virus In Vitro.Pharmaceutical research · 2019Article
- Article
- Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection.Antimicrobial agents and chemotherapy · 2018Article
- The new alchemy: Online networking, data sharing and research activity distribution tools for scientists.F1000Research · 2017Article
- Molecular mechanisms of Ebola pathogenesis.Journal of leukocyte biology · 2016Review
- Integrated Computational Approach for Virtual Hit Identification against Ebola Viral Proteins VP35 and VP40.International journal of molecular sciences · 2016Article
- Bioengineering of Tobacco Mosaic Virus to Create a Non-Infectious Positive Control for Ebola Diagnostic Assays.Scientific reports · 2016Article
- In silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease.F1000Research · 2015Article
- Machine learning models identify molecules active against the Ebola virusF1000Research · 2015Article
- Finding small molecules for the 'next Ebola'.F1000Research · 2015Article
- FDA approved drugs as potential Ebola treatments.F1000Research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent outbreak of the Ebola virus in West Africa has highlighted the clear shortage of broad-spectrum antiviral drugs for emerging viruses. There are numerous FDA approved drugs and other small molecules described in the literature that could be further evaluated for their potential as antiviral compounds. These molecules are in addition to the few new antivirals that have been tested in Ebola patients but were not originally developed against the Ebola virus, and may play an important role as we await an effective vaccine. The balance between using FDA approved drugs versus novel antivirals with minimal safety and no efficacy data in humans should be considered. We have evaluated 55 molecules from the perspective of an experienced medicinal chemist as well as using simple molecular properties and have highlighted 16 compounds that have desirable qualities as well as those that may be less desirable. In addition we propose that a collaborative database for sharing such published and novel information on small molecules is needed for the research community studying the Ebola virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.